Indian patent granted, strengthening IP protection for SPONTAN® and ROXUS®
The Indian Patent Office has formally granted LTR Pharma Patent No. 605429, titled Formulations and Methods for Treating Erectile Dysfunction. The patent protects defined formulation
Entrepreneur and Shark Tank Australia investor Nick Bell appointed Strategic Adviser
We have appointed prominent Australian entrepreneur, investor and digital-growth specialist Nick Bell as Strategic Adviser to support the commercial growth of our broader men’s health
September 2026 Quarterly: First U.S. ROXUS® Prescriptions Fulfilled
LTR Pharma Limited (ASX:LTP) has released its Quarterly Activities Report and Appendix 4C for the three months ending on 30 September 2026. The Quarter saw
Ethics approval received to test SPONTAN® in pulmonary arterial hypertension
LTR Pharma has received ethics approval for a clinical study of SPONTAN® in pulmonary arterial hypertension (PAH). PAH represents a significant global therapeutics market, estimated at
Over 2,000 SPONTAN® units dispensed under Special Access Scheme
LTR Pharma Limited (ASX:LTP) has announced that more than 2,000 bottles of SPONTAN®, our rapid-onset intranasal vardenafil spray, have been dispensed in Australia under the
First ROXUS® prescriptions fulfilled in the United States
LTR Pharma (ASX: LTP) has confirmed the first patient-specific ROXUS® prescriptions received through Mavrox, Shed’s men’s health telehealth platform, have now been fulfilled in the